The failures and lack of progress in the development of new treatments for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, are well documented. Advances in our understanding of genetics have given clear direction for the potential development of new treatments. In collaboration with The Michael J. Fox Foundation for Parkinson’s Research, industry, and academics, Charles River worked across multiple sites to understand the role of LRRK2 in Parkinson’s, and its possible inhibition. Collaborative utiliziation of all disciplines (including medicinal chemistry, molecular biology, pharmacology, and toxicology) helped to understand the risks and benefits of novel agents that offer the amazing potential to treat Parkinson’s disease.